Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
about
Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterizationEndobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing.Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer.Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysisComparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patientsPD-L1 Expression in Lung Cancer.Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.Chemotherapy remains an essential element of personalized care for persons with lung cancers.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.New Dancing Couple: PD-L1 and MicroRNA.PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis.Reflections on immune checkpoint inhibition in non-small cell lung cancer.Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer.Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Immune-related tumor response assessment criteria: a comprehensive review.Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
P2860
Q26765060-16EABC84-9FF7-4C93-B0AD-433E8604125DQ33766053-588F2C74-EBFB-40E1-B7CD-C6E5136414F3Q35922142-B7DFC8B4-FB1B-4835-B529-C4047A0B09D7Q35993134-7614688C-BBDA-4B9C-9D7A-352F561629E4Q37544396-DFE42F9E-AB8C-4D99-9387-F8BE837D22B8Q37704352-8B3A2CA2-EE54-4B01-836F-DE56EDA3EA3AQ38749966-2FF05395-F585-4F01-B65E-080CE4919BF5Q38838014-206875EA-C656-4027-A8CD-023660AB3313Q38899873-A5848CD6-2B68-4CE8-BA46-1DAACF2C4FC3Q38922208-B4750F27-3B75-4249-91C9-1414B229192EQ39413337-D6D1138B-17D7-41A3-B29A-F67BFD6B56D4Q40358673-48703A89-003A-4CE9-B559-885107B53A8DQ41341715-BC0CD25E-35C6-4513-93A7-8782A650DB83Q43195855-8C0BB01F-0C16-4C97-8E70-2184032A2A26Q46241190-05EB0FB7-3CB2-4F4F-B15F-38D7D8734CF6Q47144850-4CAE80C2-1C3C-4233-8A94-A8081DF3AF1BQ47164059-278EA7A5-1BAF-4C85-9747-AB84457568CCQ48105843-6E9CFF2D-C0DA-4CDD-A5FB-21649CBF77A2Q49434203-F61C1119-67A0-4F7C-89D9-2E7A026EFC54Q49668388-FF05C931-8251-4ED4-9607-5F0B56B695C0Q50168209-D3AAD2BE-1A59-4EF4-B6F6-B9677159ED90
P2860
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@ast
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@en
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@nl
type
label
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@ast
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@en
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@nl
prefLabel
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@ast
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@en
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@nl
P2093
P1476
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
@en
P2093
Benjamin Besse
Ecaterina Ileana
Giannis Mountzios
Giuseppe Giaccone
Stéphane Champiat
P304
P356
10.1097/JTO.0000000000000074
P407
P577
2014-02-01T00:00:00Z